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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder typified by
a massive loss of motor neurons with few therapeutic options. The exact cause of
neuronal degeneration is unknown but it is now admitted that ALS is a multifactorial
disease with several mechanisms involved including glutamate excitotoxicity. More
specifically, N-methyl-D-aspartate (NMDA)-mediated cell death and impairment of the
glutamate-transport has been suggested to play a key role in ALS pathophysiology.
Thus, evaluating NMDAR antagonists is of high therapeutic interest. Gacyclidine, also
named GK11, is a high affinity non-competitive NMDAR antagonist that may protect
against motor neuron death in an ALS context. Moreover, GK11 presents a low intrinsic
neurotoxicity and has already been used in two clinical trials for CNS lesions. In the present
study, we investigated the influence of chronic administration of two doses of GK11 (0.1
and 1mg/kg) on the survival and the functional motor activity of hSOD1G93A mice, an
animal model of ALS. Treatment started at early symptomatic age (60 days) and was
applied bi-weekly until the end stage of the disease. We first confirmed that functional
alteration of locomotor activity was evident in the hSOD1G93A transgenic female mice
by 60 days of age. A low dose of GK11 improved the survival of the mice by 4.3%
and partially preserved body weight. Improved life span was associated with a delay in
locomotor function impairment. Conversely, the high dose treatment worsened motor
functions. These findings suggest that chronic administration of GK11 beginning at early
symptomatic stage may be beneficial for patients with ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a chronic neurodegenera-
tive disease characterized by neuronal death of both lower and
upper motoneurons in the spinal cord, the brain stem and the
motor cortex. This chronic motor neuronopathy leads to progres-
sive atrophy of skeletal muscles, paralysis and ultimately to death
of the patients mainly due to respiratory failure [for review see
(Turner et al., 2013)].
Pathogenesis and mechanisms of selective vulnerability of
motoneurons in ALS are still largely unknown although, within
the past two decades, it has been demonstrated that ALS is a
complex multifactorial disease. Indeed many factors including
protein misfolding, glutamate-mediated excitotoxicity, oxidative
stress and impaired axonal transport may contribute to motoneu-
ron death in ALS [for review see Robberecht and Philips (2013)].
An excessive stimulation of glutamate receptors induces exci-
totoxic processes; this phenomenon being largely implicated in
both acute and chronic neurodegenerative diseases (Olney, 1989;
Plaitakis and Constantakakis, 1993; Mehta et al., 2013), and
in particular in ALS (Heath and Shaw, 2002; Bogaert et al.,
2010). In the objective of translation to clinics, excitotoxicity
is one of the key pharmacological targets as attested by the
only FDA-approved drug, riluzole (2-amino-6-trifluoromethoxy
benzothiazole) which is a modulator of excitatory neurotrans-
mitters activity (including glutamate) (Bogaert et al., 2010).
Glutamate interacts with a large range of specific transporters and
receptors such as N-methyl-D-aspartate receptors (NMDARs)
(Mehta et al., 2013) and a promising, but so far overlooked
therapeutic strategy, is to reduce excitotoxicity using NMDA
receptor antagonist [for review see Spalloni et al. (2013)]. The
low-affinity non-competitive NMDAR antagonist, memantine
displayed encouraging results in hSOD1G93A mice (Wang and
Zhang, 2005; Joo et al., 2007), an ALS animal model. Clinical
trials have shown that memantine is safe and well tolerated by
ALS patients (de Carvalho et al., 2010; Levine et al., 2010) but no
evidence of its efficacy had been reported yet.
Gacyclidine (GK11), a phencyclidine, is a non-competitive
NMDA receptor antagonist, with a selective affinity for NR2B
receptors, that had been shown to prevent glutamate-induced
neuronal death in vitro and is less neurotoxic than other NMDA
receptor antagonists (Hirbec et al., 2001; Vandame et al., 2007).
Moreover, in vivoGK11 exhibits neuroprotective effects following
organophosphorous nerve agents-induced convulsions (Bhagat
et al., 2005) and following spinal cord injury (Feldblum et al.,
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2000; Gaviria et al., 2000a,b; Kouyoumdjian et al., 2009; Lonjon
et al., 2010).
In this study we have evaluated the effect of chronic treatment
of two doses of GK11 on the survival and the locomotor function
of hSOD1G93A mice. We demonstrate a dose effect of GK11 on
the survival of the mice, treatment with a low GK11 dose induced
an increase in life span conversely to a high dose that reduced it.
Moreover, treatment-induced increase in survival was associated
with a reduction of locomotor function impairment whereas high
dose treatment worsened the motor phenotype.
MATERIALS AND METHODS
ANIMALS
Transgenic mice carrying the G93A human SOD1 mutation,
B6SJL-Tg (SOD1-G93A) 1Gur/J (ALS mice, high copy num-
ber) were purchased from The Jackson Laboratory (Bar Harbor,
ME, USA) and bred on a B6SJL background. Transgenic mice
were identified by PCR and housed in controlled conditions
(hygrometry, temperature and 12h light/dark cycle); the environ-
ment was not modified over the course of the protocol. Only
females were used and litter-matching between groups were done
as much as possible. We carried out all animal experiments in
accordance with the guidelines approved by the French Ministry
of Agriculture and following the European Council directive
(2010/63/UE). Every effort was made to minimize the number
and suffering of animals. Age of death was defined as functional
paralysis of both hindlimbs and a righting reflex >20 s. These cri-
teria follow the commonly accepted guide lines for working on
ALS mice (Leitner and Lutz, 2009; Solomon et al., 2011).
GK11 TREATMENTS
Twice a week, mice (transgenic and control) were intra-
peritoneally injected with either gacyclidine (two different
concentrations; 1mg/kg or 0.1mg/kg) (Neuréva, Montpellier,
France) or NaCl. The treatment doses were determined accord-
ing to the following criteria: the dose of 1mg/kg corresponds
to the acute therapeutic dose in rat (Feldblum et al., 2000;
Gaviria et al., 2000b) and we wanted to test the possible toxic
effect of a chronic administration. Repeated administration of
low dose of non-competitive NMDA receptor antagonists induces
hyperlocomotion in rat (Wolf and Khansa, 1991; Loscher and
Honack, 1992; Matsuoka et al., 2005). Injections were thus not
done daily not only to reduce the risk of peritonitis but also to
prevent possible interference of injections with behavioral tests.
Treatment started at 60 days of age and was carried until the
death of the animal. Number of mice: controls injected with
GK11 (0.1mg/Kg, n = 10; 1mg/Kg, n = 5) or NaCl (n = 14);
transgenicmice injected with GK11 (0.1mg/Kg, n = 15; 1mg/Kg,
n = 5) or NaCl (n = 21).
BEHAVIORAL ANALYSIS
Catwalk
We used the CatWalk™ (Noldus, Wageningen, The Netherlands)
to study dynamic and voluntarily walking patterns of the mice. As
previously described (Gerber et al., 2012a) we selected amongst
locomotor patterns, the “relative position” that corresponds to
the distance between the placement of front and hind paws over
one walking step. For data collection, six runs per animal were
performed on a weekly basis from day 60 (just prior the first
injection) and until animals were not able to correctly cross the
walkway due to hindlimb paralysis. For each mouse, a minimum
of three runs crossed at the same speed with 3-full step sequence
patterns per run were recorded. To accustom the animals to the
environment and thus to avoid bias due to stress, we placed trans-
genic and control littermates mice on the CatWalk 7 and 3 days
prior to the first recording session. Catwalk analyses started before
the first injection, the next behavioral session was done at least
72 h after treatment. Recordings were performed until the failure
to obtain satisfactory paw patterns with the CatWalk analysis sys-
tem due to hindlimb paralysis and thus absence of paw detection
in the transgenic groups. Data analysis was done in collaboration
with InnovationNet (Tiranges, France).
Open field activity
Spontaneous locomotor activity of mice was monitored in an
open field test. Animals were placed in an empty test arena
(45 × 45 cm box) and movements automatically recorded. We
analyzed the total distance (cm) (Bioseb, Open field, Actitrack
software, Vitrolles, France). Recording sessions started at P53 and
until the end of life of the transgenic mice; analysis correspond
to a weekly 8min’ sessions preceded by 2min without recordings
to avoid any bias due to stress. Open field test were performed
on a weekly basis, 48 h after the injection. Recording sessions
were performed until mice were unable to move in the test
arena
STATISTICAL ANALYSIS
Kaplan Meier analysis and log-rank test were applied for sur-
vival curves (Figure 1A). Two ways ANOVA followed by Tukey-
Kramer test was used for all analysis that consist on a com-
bination of a treatment (at three different doses, NaCl, GK11
0.1mg/kg and GK11 1mg/kg) on two distinct genotypes over
time (Figures 1B, 2B, 3A–C, 4). From 116 days onward trans-
genic and control mice could not be directly compared due
to speed differences, moreover due to death GK11 1mg/kg-
treated transgenic mice were not included from P123 onwards.
We thus used one way ANOVA followed by Tukey-Kramer test
for Figure 3D and one way ANOVA followed by Mann-Whitney
test for Figures 3E,F. For all analysis at P60 i.e., before the
treatment started t-test was done (Figures 1A, A1). CatWalk
data consist on replicates of a minimum of 3 and a maxi-
mum of 6 runs (same speed with 3 full step sequence) per
animal in all cases these values were averaged. Experiments were
designed to reach a 95% power to detect a 10% or greater dif-
ference between groups. We used GraphPad Prism version 5.03
(GraphPad software, CA, USA, and Minitab 15, Minitab Inc,
USA).
RESULTS
DOSE EFFECT OF GACYCLIDINE ON THE SURVIVAL OF THE MICE
We first assessed the influence of a chronic treatment with GK11
(0.1mg/kg), a non-competitive NMDA receptor antagonist, on
the survival of hSODG93A female mice. Animals treated with
GK11 display an increased survival as compared to animals
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FIGURE 1 | Dose effect of Gacyclidine on hSOD1G93A mice survival and
weight. (A)—Kaplan-Meier curves of hSOD1G93A mice injected i.p with
NaCl (n = 21), GK11 0.1mg/kg (n = 15) or GK11 1mg/kg (n = 5).
(B)—Weight changes (g) in control (dash line) and transgenic mice
(continuous line) injected with NaCl, GK11 0.1mg/kg or GK11.1mg/kg.
Two-ways ANOVA followed by Tukey-Kramer test [F(10, 695)=96.18]. Weight
of NaCl treated controls and transgenics significantly differs from P109
whereas weight of GK11 (both doses) treated controls and transgenics
significantly differ from P123. ∗p < 0.05 and ∗∗∗p < 0.001.
injected with NaCl. Median survivals are indeed of 146 and 140
for mice injected with GK11 and NaCl respectively; this represent
a significant 4.3% increase in life span (Kaplan Meier, P-value =
0.0341) (Figure 1A).
To evaluate the possible toxicity margin of the molecule, we
injected mice with a 1 log higher GK11 concentration (1mg/kg).
Mice chronically injected with this high dose show a signifi-
cant decrease in lifespan as compared to the littermates injected
with NaCl. Median survivals are indeed of 129 and 140 for mice
injected with GK11 and NaCl respectively; this represents a signif-
icant 7.9% decrease in life span (Kaplan Meier, P-value = 0.006)
(Figure 1A).
Over the progression of the disease, transgenicmice lost weight
due to muscular atrophy. We monitored body weight changes
from P60 until death. NaCl injected transgenic mice weight dif-
fers significantly from those of the NaCl injected control group
FIGURE 2 | Locomotor function analysis of hSOD1G93A female mice.
(A)—CatWalk gait analysis. Graph represent the distance between the front
and hind paws on a step sequence (“relative position”) of control females
(n = 32) and hSOD1G93Aanimals (n = 41) before treatment. Statistics:
t-test: *p < 0.05 (B)—Open field test. Spontaneous locomotor activity
represented by the mean distance covered by control female and
hSOD1G93A mice in a weekly 8min recording test over disease
progression. For Open field test a minimum of 10 animals were used from
day 53 to 130, then due to the death of hSOD1G93A mice, a minimum of 5
animals were analyzed (P137). Statistics: two ways ANOVA followed by
Tukey Kramer test. F(12, 262)=95.95. ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
from P109 whereas weight of GK11 treated transgenic mice (both
doses) is significantly different from GK11 treated control mice
from P123 (Figure 1B). There is no effect of GK11 treatment on
the body weight of control mice.
We thus evidence a beneficial effect of a chronic low dose of
GK11 on the survival of hSOD1G93A female mice whereas a high
dose of GK11 has a detrimental effect.
LOCOMOTOR FUNCTION IS ALTERED AT 60 DAYS OF AGE IN FEMALE
hSOD1G93A MICE
In the perspective of translational studies, it is important to
apply the therapeutic strategy at early symptomatic period.
Experiments were done on female mice, it was thus mandatory to
thoroughly characterize disease onset and progression in female
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FIGURE 3 | Evaluation of Gacyclidine effects on hSOD1G93A mice motor
pattern: CatWalk gait analysis. Graphs represent the distance between the
front and hind paws on a step sequence (“relative position”). (A—C)—control
and hSOD1G93A animals (NaCl, GK11 0.1mg/kg or GK11 1mg/kg
treated)—Respectively at 67, 95, and, 109 days of age. (D)—hSOD1G93A
animals (NaCl, GK11 0.1mg/kg or GK11 1mg/kg injected) at 116 days. (E, F)
hSOD1G93A animals (NaCl or GK11 0.1mg/kg injected) at 123 and 130 days. A
minimum of 4 and up to 24 animals per time point were analyzed from 67 to
116 days of age; recording were stopped for GK 11 1mg/kg after P116 due to
hindlimb paralysis. Then due to progression of the paralysis a minimum of 8
and up to 15 animals per time point were analyzed from 123 to 130 days of
age. Statistics: (A–C): two ways ANOVA followed by Tukey Kramer test. D:
one way ANOVA followed by Tukey Kramer test. (E,F): one way ANOVA
followed by Mann-Whitney test. ∗p < 0.05.
hSOD1G93A mice. We have used the previously described combi-
nation of CatWalk and open field analysis (Gerber et al., 2012a)
to evaluate locomotor alterations. To compare with our former
motor analysis on male hSOD1G93A mice, we tested the female
mice on a weekly basis from 60 days of age and selected the same
parameters. We quantified the spontaneous motor activity using
the open field system and the “relative position” of the paws (dis-
tance between front and hind footprints over a step cycle) using
the CatWalk system.
As a prerequisite for accurate CatWalk investigation, we veri-
fied if the B6SJL strain is suitable for gait analysis. In that aim, we
analyzed the stride of control females from P60 to P130. It had
indeed been shown that stride must remain stable in control mice
all along the study protocol to avoid any misleading conclusions
(Clarke and Still, 1999). The stride remains identical throughout
our study (Table A1).
At 60 days of age hSOD1G93A female mice present an alteration
in gait pattern appearing as the inability to draw their hind limbs
up to the previous position of their front limbs (Figure 2A) This
alteration increased further up to 109 days of age (Figures 3A–C,
SOD NaCl vs. control NaCl). To evaluate the spontaneous motor
activity of hSOD1G93A and control mice, we used the open field
system. We evidence a decreased in the mean distance covered by
transgenic animals as compared to their control littermate from
P116 (Figure 2B).
Combination of CatWalk and open field analysis allows an
accurate description of motor alterations and permit to identify
gait pattern alteration, and thus clinical onset of the disease, at 60
days of age. This is in agreement with our previous results in male
hSOD1G93A mice (Gerber et al., 2012a) (Figure A1).
INCREASED LIFE SPAN CORRELATED WITH DELAYED MOTOR DEFICITS
We then used the CatWalk system to tentatively correlate the
effects of the drug on the lifespan with modification of disease
onset and/or progression of the disease; we compared locomotor
functions of transgenic hSOD1G93A females injected with either
GK11 (0.1mg/kg or 1mg/kg) or NaCl. In parallel, we evalu-
ated whether GK11 had an effect on non-transgenic animal by
comparing treated versus NaCl injected control mice.
From 67 days to 109 days, the relative position is identical in
transgenic groups injected with GK11 0.1mg/kg or 1mg/kg com-
pared to transgenic mice injected with NaCl. Controls animals
of all groups (GK11 0.1mg/kg, 1mg/kg or NaCl) remain stable
over the same period. However, transgenic mice (0.1mg/kg and
NaCl) show an alteration of the motor pattern when compared
to their respective controls that increased from 95 to 109 days
of age. At 109 days, transgenic mice injected with GK11 at high
concentration show a critically altered phenotype compared not
only to controls but also to the transgenic group injected with
NaCl (Figures 3A–C). From 116 days onward, due to hindlimb
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FIGURE 4 | Evaluation of Gacyclidine effects on the spontaneous motor
activity of hSOD1G93A mice: Open Field analysis. Spontaneous locomotor
activity represented by the mean distance covered by female controls and
hSOD1G93A mice in a weekly 8min recording test over disease progression
included. (A,B)—Control and hSOD1G93A mice injected with NaCl or GK11
0.1mg/kg. (C,D)—Control and hSOD1G93A mice injected with NaCl or GK11
1mg/kg. A minimum of 5 animals were analyzed per time point. Statistics:
two ways ANOVA followed by Tukey Kramer test.
paralysis, transgenic and control mice do not achieve the CatWalk
test at the same speed and thus, referring to Clarke’s et al. study
(Clarke and Still, 1999), cannot be compared. We thus ana-
lyzed separately hSOD1G93A and control mice. At 116 days, mice
injected with GK11 1mg/kg show an altered phenotype compared
to the NaCl injected mice (Figure 3D). No satisfactory recording
sessions were obtained for the GK11 1mg/kg from P123 onwards
(Figures 3E,F). GK11 0.1mg/kg treated mice exhibit a reduction
of locomotor function impairment compared to the transgenic
NaCl group at P130 (Figure 3F). No difference between control
groups were seen over the same period (data not shown). These
results suggest that treatment with a low dose of GK11 induces
a slight but significant delay in hindlimb paralysis progression.
Oppositely, treatment with a high dose of GK11 worsened the
motor pattern.
We used an open field system to measure the spontaneous
locomotor activity of control and transgenic mice. No difference
has been noted in the mean crossed distances when we compared
both GK11 doses (0.1 and 1mg/kg) and NaCl injected mice for
both control and transgenic groups (Figures 4A–D).
DISCUSSION
Glutamate mediated excitotoxicity is involved in ALS patho-
genesis (Foran and Trotti, 2009) and several studies have eval-
uated the pharmacological profile of a number of molecules
acting on glutamate release and transport [for review (Corona
et al., 2007; Bogaert et al., 2010)]. Gacyclidine (GK11), a non-
competitive NMDA receptor antagonist, has already been used
in the clinics (Hirbec et al., 2001; Tadie et al., 2003; Lepeintre
et al., 2004) and a single GK11 dose of 1mg/kg has demon-
strated neuroprotective effects on a model of photochemi-
cal spinal cord injury (Gaviria et al., 2000b). Chronic GK11
administration has never been reported. In view of these data,
we decided to analyze the impact of a chronic treatment of
GK11 on the survival and locomotor activity of hSOD1G93A
mice.
Our study clearly shows a dose response effect; indeed
although a high GK11 dose is detrimental by shortening the life
span of the mice by 7.9%, a low dose induces a 4.3% increase in
survival vs. controls. Moreover, this increased life span is asso-
ciated with a reduction in walking pattern deficits whereas high
dose treatment worsened the motor phenotype.
GENDER EFFECTS ON SURVIVAL AND FUNCTIONAL DEFICITS IN THE
SOD1G93A MOUSE MODEL OF ALS
We have recently carried out a thorough analysis analyses of sur-
vival and motor function in hSOD1G93A male mice (Gerber et al.,
2012a,b). For the present study we have used females. Transgenic
females survive significantly longer than males; median sur-
vivals were of 129 and 140 days for males and females respec-
tively. Comparison with a previous study (Heiman-Patterson
et al., 2005) attests for the stability of this mouse model; indeed
Frontiers in Cellular Neuroscience www.frontiersin.org December 2013 | Volume 7 | Article 280 | 5
Gerber et al. gacyclidine effects on SOD1G93A mice
reported life span was of 128 and 133 days for males and females
respectively.
We have evaluated locomotor function of female hSOD1G93A
mice using the same combination of dynamic walking patterns
and spontaneous motor activity analysis as previously done with
males (Gerber et al., 2012a). As for males, we detect early func-
tional deficits that confirm symptoms onset at 60 days of age,
i.e., 20 days earlier than previously described (Figure A1). Indeed,
dynamic gait analysis using the CatWalk system demonstrates
alteration in gait pattern for both males and females from 60
days onwards. Spontaneous motor activity evaluated with an
open field highlighted a decrease in the mean distance covered
by transgenic animals as compared to their control littermate
from 116 days onwards for females as compared to 102 days
of age onwards for males (Gerber et al., 2012a). This difference
may reflect gender-specific mechanism of synaptic impairment
since a recent study demonstrated sexual dimorphism in the
decline of the presynaptic machinery at an early symptomatic
stage (Naumenko et al., 2011). Mean survival of hSOD1G93A mice
is of 140 days for female as compared to 129 days for males
(Gerber et al., 2012a), however, even if female mice survive longer
than male counterparts, early motor symptoms impairment are
detected at 60 days of age in both gender.
ANTIGLUTAMATE DRUGS
One of the popular hypothesis regarding mechanisms involved
in ALS is that an excessive activation of glutamate receptors
may be responsible for motoneuron death (Corona et al., 2007).
NMDA receptors are known for their permeability to cations
and in particular to calcium; their over activation leading to
excitoxic phenomenon. Recent findings have shown that sub-
types of AMPA receptors, that either do not express the GluR2
subunit or express an edited form of this subunit, present a sim-
ilar permeability to calcium than NMDA receptors (Van Den
Bosch et al., 2000; Kawahara et al., 2006; Corona et al., 2007).
These AMPA receptor subtypes are widely expressed in motoneu-
rons and are therefore involved in excitotoxic processes (Carriedo
et al., 1996; Gerardo-Nava et al., 2013). However, modulating
AMPA excitoxicity mediated pathway is mostly ineffective in clin-
ical trials and induce various side effect (such as dizziness and
Ataxia) [for review see (Chang et al., 2012)]. Nevertheless, peram-
panel, a non-competitive AMPA receptor antagonist to AMPAR
is very promising in the treatment of epilepsy (Rogawski, 2011).
Several antiglutamate drugs have been evaluated in ALS [for
review see (Gibson and Bromberg, 2012)]. Riluzole is the only
approved treatment and prolongs median survival by about 2
to 3 months in ALS patients (Miller et al., 2012) and by 10.5%
in mice (Gurney et al., 1996). Riluzole induces an inhibition
of glutamate release and modulation of both alpha-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-
methyl-d-aspartate (NMDA) receptors (Jin et al., 2010; Cifra
et al., 2013). However, Riluzole displays other diverse and multi-
ple non-specific pharmacological properties (Cheah et al., 2010)
that may cause adverse effects such as nausea, asthenia and raised
alanine transferase (Miller et al., 2012). As recently pinpointed
(Spalloni et al., 2013) the role of NMDA receptors activation
in ALS has not received much attention, even if a low affinity
non-competitive NMDAR antagonist, memantine, has shown
promising results in an ALS animal model. In this context, evalu-
ations of new therapeutic agents are of utmost importance. GK11,
a high affinity uncompetitive NMDAR antagonist, presents a low
intrinsic neurotoxicity, paucity of side effects attributed to its
selectivity for NR2 B containing receptors (Vandame et al., 2007).
No interaction was found with glutamatergic AMPA, kainate, or
σ1 and σ2 receptors (Hirbec et al., 2001).
In our study, early symptomatic (starting at P60) bi-weekly
chronic administration of a low dose of GK11 (0.1mg/kg) yields
a 4.3% increase in the life span of the female hSOD1G93A mice.
These results are similar to the effects of memantine (Wang and
Zhang, 2005; Joo et al., 2007). Conversely to memantine (Joo
et al., 2007), increase in survival induced by GK11 is associated
with a significant protective effect on locomotor deterioration
at the end stage of the disease. Of particular interest is the
fact that, to-date, GK11 is the most specific NMDA receptor
antagonist efficient in an animal model of ALS, thus definitely
pinpointing the involvement of this receptor in the pathogene-
sis of the disease. High dose GK11 treatment leads to a decrease
in the life span of female hSOD1G93A associated to a more
abrupt development of motor symptoms and hindlimb paral-
ysis. Importantly, high dose drug treatment has no effect on
weight loss, CatWalk or open field performances in the con-
trol group as reported in a recent study in rats undergoing an
acute treatment (Vandame et al., 2013). This toxic side effect
might reflect an induction of specific cascade events in the SOD
context.
In conclusion, we demonstrate here that a chronic administra-
tion (starting at early symptomatic stage) of a non-competitive
NMDA receptors antagonist significantly increases the survival
of a mouse model of ALS. Indeed, a chronic low dose of GK11
prolongs the life span and reduces weight loss and motor deficits
in hSOD1G93A female mice. These results, combined with those
from previous studies on CNS injury, demonstrating in patients a
relative efficacy and the absence of side effects (Tadie et al., 2003;
Lepeintre et al., 2004), suggest that low dose of GK11 could be
used as a new and effective NMDA receptor antagonist for ALS
patients.
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APPENDIX
FIGURE A1 | Locomotor function analysis of hSOD1G93A female and
male mice. CatWalk gait analysis. Graph represent the distance between
the front and hind paws on a step sequence (“relative position”) of control
males (n = 16), hSOD1G93A males (n = 11), control females (n = 32) and
hSOD1G93A animals (n = 41) at 60 days of age. Statistics: t-test: ∗p < 0.05.
Table A1 | Frontlimb and hindlimb stride (mm) of control mice at P60
(n = 22), Control NaCl at P81 (n = 12), P109 (n = 13) and P130
(n = 11).
Colonne1 P60 P81 P109 P130
Frontlimb
(mm)
58.81 ± 1.275 59.00 ± 1.317 59.14 ± 1.549 61.48 ± 2.053
Hindlimb
(mm)
59.28 ± 1.393 59.27 ± 1.372 59.14 ± 1.507 61.20 ± 1.945
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